Abivax (AAVXF) Receivables - Other (2021 - 2026)

Abivax has reported Receivables - Other for 6 years, with the latest figure at $16.1 million in Q1 2026.

• On a quarterly basis, Receivables - Other fell 28.95% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 28.95% decrease from a year earlier, with the FY2025 full-year figure at $15.3 million, down 24.23% from the prior year.
• Receivables - Other was $16.1 million for Q1 2026 at Abivax, up from $15.3 million in the prior quarter.
• The five-year high for Receivables - Other was $26.7 million in Q4 2023, with the low at $9.4 million in Q4 2022.
• Average Receivables - Other over 5 years is $19.5 million, with a median of $20.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other plunged 44.31% in 2022, then soared 183.84% in 2023.
• Over 5 years, Receivables - Other stood at $9.4 million in 2022, then soared by 183.84% to $26.7 million in 2023, then slipped by 24.46% to $20.2 million in 2024, then fell by 24.23% to $15.3 million in 2025, then gained by 5.34% to $16.1 million in 2026.
• The last three Receivables - Other figures came in at $16.1 million (Q1 2026), $15.3 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.